Ovarian Cancer Drug Trial Results Released
Researchers tested two combination therapies for recurrent epithelial ovarian cancer to see if they halted disease progression.
Updated on Oct. 13, 2026 in Cancer
A phase II clinical trial evaluated two different multi-drug regimens for patients with recurrent epithelial ovarian cancer. The study assessed how effectively these treatments controlled the disease.
Why it matters
Understanding how these specific drug combinations perform helps medical teams refine treatment strategies for recurrent disease. Identifying why some patients show exceptional responses remains a focus of ongoing oncology research.
In a phase II trial of 68 patients with recurrent epithelial ovarian cancer, researchers compared a three-drug regimen to a two-drug regimen. Both arms demonstrated a median progression-free survival of 4.5 months, with limited evidence connecting specific genomic markers to outcomes.
The players
Durvalumab
An immunotherapy agent often used to block proteins that help cancer cells avoid the immune system.
Olaparib
A PARP inhibitor designed to prevent cancer cells from repairing their damaged DNA.
Cediranib
An anti-angiogenic medication that works by inhibiting the growth of new blood vessels that feed tumors.
The details
The trial investigated durvalumab, olaparib, and cediranib to determine their impact on recurrent cancer. Researchers utilized whole exome sequencing on pre-treatment biopsies and blood samples to compare genomic profiles against clinical response. Despite the evaluation of genetic factors like TP53 mutations, no consistent link was found between baseline genomic alterations and the observed clinical benefit.
Timeline
October 13, 2026: Study results published.
Health Landscape
This study follows the standard protocol used in the National Cancer Institute's phase II clinical trial infrastructure. It adds to the growing body of research investigating targeted drug combinations as potential interventions for patients with recurrent gynecologic malignancies.
If you are managing recurrent ovarian cancer, this study highlights the importance of clinical trial participation for access to experimental combination therapies. These findings should be used as a basis for a conversation with your oncologist regarding your specific genomic profile and care options.
The takeaway
While clinical trials offer new pathways for treatment, results regarding drug combinations and genomic predictors remain complex. Patients should work closely with their oncology team to review all available clinical trial options that align with their specific medical history.
Further reading
For more information on the latest developments in research, visit our section on Cancer.
More information
Review the full study details on the NCBI clinical trial data page.
